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 Implant-associated infections are caused by microor-
ganisms growing in bioﬁ lms, rendering these infections 
difﬁ cult to diagnose and to eradicate. Delayed-onset 
low-grade infection is difﬁ cult to distinguish from asep-
tic failure, often presenting without signs of infection, 
but only with early loosening and persisting pain. A 
combination of criteria is needed for an accurate diag-
nosis: clinical signs and symptoms, laboratory signs of 
infection, microbiology, histology, and imaging. The 
treatment goals in prosthetic joint–associated infection 
are eradication of infection and an optimal functional 
result. The goal in internal ﬁ xation device–associated 
infection is consolidation of the fracture and avoid-
ance of chronic osteomyelitis. Successful treatment 
requires an adequate surgical procedure combined with 
long-term antimicrobial therapy, ideally with an agent 
acting on adhering bioﬁ lm microorganisms. This article 
reviews the epidemiology, pathogenesis, diagnosis, and 
management of implant-associated infections, and pres-
ents pathogenesis and risk of hematogenous infection.
 Introduction
 Perioperative antimicrobial prophylaxis, advanced 
device design, improved surgical technique, and laminar 
airfl ow operating room environments have substantially 
decreased the rate of implant-associated infections. Nev-
ertheless, with increasing numbers of implanted devices, 
the absolute number of implant-associated infections is 
steadily increasing [ 1 ]. In patients with primary joint 
replacement, the infection rate during the fi rst 2 years 
is currently less than 1% in hip and shoulder prosthe-
ses, less than 2% in knee prostheses, and less than 9% 
in elbow prostheses [ 2 ]. About 5% to 10% of inserted 
internal fi xation devices become infected; the incidence 
of infection after internal fi xation of closed fractures is 
generally lower (0.5%–2%), whereas the incidence may 
exceed 30% after fi xation of grade 3 open fractures. 
Because the follow-up in most published series is lim-
ited to a few years, and many cases of presumed aseptic 
failure may be due to infection, the actual incidence of 
device-associated infection is likely higher.
 In addition, infection rates after revision surgery 
are usually considerably higher than after primary 
replacement. Prosthetic joints remain susceptible to hema-
togenous seeding during their entire lifetime and some 
perioperative infections may have a latency period longer 
than 2 years. Therefore, for accurate comparisons, the 
frequency of infection should be reported as incidence 
rate (per prosthesis-years) rather than as risk (without 
specifi ed denominator). The incidence of infection per 
1000 prosthesis-years involving hip and knee prostheses 
was 5.9 (95% CI: 5.3–6.5) during the fi rst 2 years after 
implantation and 2.3 (95% CI: 2.1–2.5) during the fol-
lowing 8 years [ 3 ]. 
 Pathogenesis
 Implant-associated infections are caused by microorgan-
isms growing in biofi lms, which live attached to a surface 
in a highly hydrated extracellular matrix. Within biofi lms, 
microorganisms develop into organized and complex 
communities with structural and functional heterogeneity 
resembling multicellular organisms. Release of cell-to-cell 
signaling molecules (quorum sensing) allows microorgan-
isms in a biofi lm to respond in concert by changing their 
gene expression involved in biofi lm differentiation. Deple-
tion of metabolic substances causes microbes to enter into 
a stationary state, rendering them up to 1000 times more 
resistant to most antimicrobial agents than their plank-
tonic (free-living) counterparts [ 4 ]. 
 Implant-associated infections occur either by direct 
inoculation into the surgical wound during surgery 
or immediately thereafter (perioperative infection); by 
microbial spread through blood from a distant focus of 
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infection (hematogenous infection); by direct spreading 
from an adjacent infectious focus; or due to penetrating 
trauma (contiguous infection).  Table 1 shows the classi-
fi cation of implant-associated infections according to the 
onset of symptoms after implantation and the most com-
mon causative organisms. 
 Defi nition of Infection
 Staphylococci are the most frequent infective agents, 
followed by streptococci, enterococci, gram-negative 
bacilli, and  Propionibacterium acnes [ 2 , 3 ]. In prosthetic 
joint infections, early infection is defi ned as appear-
ance of the fi rst signs and symptoms of infection at the 
implant site less than 3 months after surgery. This type 
of infection mainly occurs by the exogenous route, and is 
generally caused by highly virulent microorganisms (eg, 
 Staphylococcus aureus ). Delayed (low-grade) infection is 
defi ned as appearance of the fi rst manifestation of infec-
tion 3 to 24 months after surgery. In most such cases, 
microorganisms of low virulence (eg, coagulase-negative 
staphylococci,  P. acnes ) are inoculated during surgery. 
Late infection is defi ned as the appearance of the fi rst 
signs and symptoms of infection more than 24 months 
after surgery; most of these infections result from hema-
togenous seeding from a distant focus. 
 Infections associated with internal fi xation devices 
are classifi ed as early (< 2 weeks), delayed (2–10 weeks), 
and late (> 10 weeks) [ 5 ]. These infections generally 
occur exogenously, either by the penetrating trauma 
itself, during insertion of the fi xation device, or dur-
ing disturbed wound healing. Hematogenous infection 
is less frequent and is mainly caused by bacteremia 
originating from skin, respiratory, and urinary tract 
infection. Early infections are mainly caused by highly 
virulent organisms such as  S. aureus or gram-negative 
bacilli, whereas delayed and late infections are mainly 
caused by microorganisms of low virulence (eg, coagu-
lase-negative staphylococci). 
 Diagnostic Workup
 Laboratory parameters
 The blood leukocyte count and differential are not suffi -
ciently discriminative to predict the presence or absence 
of infection. In Europe, the erythrocyte sedimentation 
rate is no longer used routinely as a diagnostic tool to 
detect infection. Serum C-reactive protein (CRP) is ele-
vated after surgery, and returns to normal within weeks; 
therefore, repetitive measurements are more informa-
tive than a single postoperative value. An increase of 
C-reactive protein after an initial postoperative decline 
is highly suggestive of infection. The role of procalcito-
nin was mainly investigated in patients with respiratory 
tract infection, but its value in prosthetic joint infection 
has not yet been defi ned.
 Synovial fl uid leukocyte count and differential repre-
sents a simple, rapid, and accurate test for differentiating 
prosthetic joint–associated infection from aseptic failure. 
The cut-off values for diagnosing prosthetic joint infection 
are considerably lower than the one for septic arthritis 
in native joints. A synovial fl uid leukocyte count greater 
than 1.7 × 10 3 / μ L and differential greater than 65% neu-
trophils had a sensitivity for diagnosing prosthetic joint 
infection of 94% and 97%, and specifi city of 88% and 
98%, respectively [ 6 ]. 
 Histopathology
 Histopathologic examination of the tissue surrounding 
the implant demonstrates a high sensitivity (> 80%) and a 
high specifi city (> 90%) [ 2 ]. Acute infl ammation has been 
variably defi ned as from 1 to 10 or greater neutrophils per 
high-power fi eld. Because the degree of infi ltration with 
infl ammatory cells may considerably vary between tissue 
sections, at least 10 high-power fi elds should be examined 
to obtain an average count. A major limitation of histo-
pathology examination is the lack of identifi cation of the 
causative microorganism, an essential element in selecting 
appropriate antimicrobial therapy. Furthermore, inter-
pretation of tissue histopathology from patients with an 
 Table 1. Classiﬁ cation of implant-associated infections according to the onset of symptoms after implantation 
 Classiﬁ cation 
 Prosthetic 
joint infections 
 Infections 
associated 
with fracture 
ﬁ xation devices  Pathogenesis  Typical microorganisms 
 Early infection   < 3 mo  < 2 wk  During implant surgery or 
the following 2–4 days 
 Highly virulent organisms such as 
Staphylococcus aureus or gram-
negative bacilli 
 Delayed infection   3–24 mo  2–10 wk  During implant surgery with 
delayed manifestation 
 Less virulent organisms such as 
coagulase-negative staphylococci 
or Propionibacterium acnes 
 Late infection   > 24 mo  > 10 wk  Predominantly caused by 
hematogenous seeding 
from remote infections 
 Typically caused by virulent 
microorganisms such as 
S. aureus, streptococci, or 
gram-negative bacilli 
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underlying systemic infl ammatory disorder (eg, rheuma-
toid arthritis or psoriasis) may be diffi cult. 
 Microbiology
 Preoperative aspirate of fl uid collections and intraopera-
tive tissue cultures provide the most accurate specimens 
for detecting the infecting microorganism. At least three 
intraoperative tissue areas should be sampled for micro-
biology. Swabs are not adequate because of their low 
sensitivity. If possible, the clinician should discontinue 
any antimicrobial therapy at least 2 weeks before tissue 
sampling for culture. 
 Using sonication to dislodge microorganisms from 
the surface of explanted devices signifi cantly increases 
the sensitivity of culture, especially when a patient is 
receiving antimicrobial treatment. When explanted 
implants were sonicated in polyethylene bags, the culture 
sensitivity of the sonication fl uid was superior to that of 
standard periprosthetic tissue (75% vs 54%), but speci-
fi city was insuffi cient due to bag leakage contaminating 
the sonication fl uid [ 7 ]. Therefore, specimen sonication 
in bags should be avoided [ 8 , 9 ]. When sonications of 331 
explanted hip and knee prostheses were studied in solid 
containers, the sensitivity of sonication fl uid cultures was 
higher than those of periprosthetic tissue (79% vs 61%, 
 P < 0.001) with specifi cities for both of 99% [ 10•• ]. 
Implant sonication was especially helpful in patients who 
received prior antimicrobial therapy. In addition, soni-
cate cultures identifi ed mixed infections more frequently 
than periprosthetic tissue cultures, indicating that at 
least some mixed infections were previously missed by 
conventional tissue cultures. In addition, more than one 
morphologic type of the same organism was frequently 
found in sonicate cultures, indicating that microorgan-
isms exist in biofi lms in different growth stages on a 
continuous scale. Interestingly, some morphologic types 
exhibit different antimicrobial susceptibility; however, 
the relevance of this needs to be determined. Quantita-
tive molecular methods (eg, polymerase chain reaction) 
may further facilitate the diagnosis, especially in patients 
receiving antimicrobial treatment [ 11 ]. 
 Imaging studies
 Radionuclide studies depict physiologic processes pre-
ceding anatomic changes. Bone scintigraphy with  99m Tc 
alone is not useful to detect implant-associated infection 
due to its low specifi city [ 12 ]. During the fi rst postopera-
tive year, increased bone remodeling is normally present 
around the prosthesis. In addition, aseptic loosening 
cannot be differentiated from infection. Therefore, bone 
 99m Tc scintigraphy should be combined with  99m Tc-cipro-
fl oxacin (Infecton) scan, with  99m Tc-hexamethylpropylene 
amine oxime (HMPAO) leukocyte scintigraphy, or with 
 99m Tc-labeled antigranulocyte monoclonal antibodies. 
The values for sensitivity, specifi city, and accuracy were 
94%, 83%, and 89% for Infecton, and 63%, 97%, and 
77% for labeled leukocytes [ 13 ]. Similarly, in another 
study, scintigraphy with  99m Tc-labeled monoclonal anti-
granulocyte antibodies had an accuracy of 81% to detect 
prosthetic joint infection [ 14 ]. However, this technique is 
not available in the United States. 
 The role of fl uorine-18-fl uorodeoxyglucose  positron 
emission tomography for differentiation of infection and 
aseptic loosening in total hip arthroplasty is still contro-
versial. Whereas Love et al. [ 15 ] reported a low specifi city 
of 9% and a high sensitivity of 100%, Stumpe et al. [ 16 ] 
found a high specifi city of 83% and a low sensitivity of 
28%. Obviously, this technique needs further evaluation 
for implant imaging.
 Conventional radiographs are of limited value in 
the workup of prosthetic joint-associated infection. Low 
specifi city is the main limitation, because radiolucency, 
osteolysis, and migration are observed not only in patients 
with infection, but also in those with aseptic loosening 
[ 16 ]. By performing serial radiographs, prosthetic migra-
tion can be measured. Rapidly progressive periprosthetic 
osteolysis and/or irregular periprosthetic osteolysis are 
suggestive for infection [ 16 ]. 
 Contrast arthrography is useful in the assessment of 
implant stability in patients with total hip arthroplasty 
[ 17 ]. During the procedure, synovial fl uid can be sampled 
for differential cell counts and microbiologic analysis. 
Synovial outpouchings and abscesses are typical signs of 
infection. The resolution may be improved by using digi-
tal subtraction technique. 
 Ultrasonography can be used to detect synovial fl uid 
and to guide joint aspiration and drainage procedures. It 
is especially helpful in prosthetic hip infection in which 
effusion cannot be clinically diagnosed. 
 Computed tomography (CT) facilitates the detection 
of joint effusion, sinus tracts, soft tissue abscesses, bone 
erosion, and periprosthetic lucency, although metallic 
artifacts reduce image quality. By using a special tech-
nique, such artifacts can be minimized, allowing detection 
of loosening and signs of soft tissue infection.
 Magnetic resonance imaging (MRI) can be safely 
used in patients with nonferromagnetic implants. MRI 
displays greater resolution for soft tissue abnormalities 
than CT or radiography, and greater anatomic detail 
than radionuclide scans. Similar to CT, the main disad-
vantages of MRI are imaging interferences in the vicinity 
of metal implants. 
 Management
 General aspects
 The treatment goal is an infection-free, pain-free, functional 
joint. Thus, neither lifelong suppressive antimicrobial ther-
apy nor prosthesis removal without replacement reaches this 
goal. In some centers, the standard treatment of prosthetic 
joint–associated infection still includes either a two-stage 
prosthesis exchange with meticulous removal of all foreign 
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material combined with a 6-week course of intravenous 
antibiotics or retention of the prosthesis combined with 
long-term suppressive antibiotic treatment [ 18 ]. However, 
according to newer studies and concepts, this approach is 
no longer justifi ed. The least invasive procedure resulting 
in cure—not merely suppression of infection—should be 
chosen, combined with long-term antimicrobial treatment 
[ 19–21 ]. The cornerstone of successful treatment is an 
early microbiologically confi rmed diagnosis, because surgi-
cal treatment can be less invasive in patients with a short 
history of infection (see below). This can be achieved by a 
high degree of clinical suspicion and avoidance of empirical 
antibiotic therapy without unequivocal diagnosis. 
 Surgical interventions
 Due to the heterogeneity of the cases, no controlled tri-
als comparing different surgical options are available or 
will likely be available in the future. Therefore, surgical 
treatment is generally based on personal experience of 
orthopedic surgeons and differs considerably between indi-
vidual centers. Nevertheless, current concepts are based on 
in vitro experiments, animal models, observational clinical 
studies, and a controlled trial [ 19–24 ]. The fi rst question 
is whether the treatment goal is curative (elimination of 
microorganisms) or palliative (suppression of bacterial 
growth).  Figure 1 shows the algorithm for the optimal 
strategy in each clinical situation; this algorithm has been 
validated in two cohort studies involving infections of total 
hip and knee prosthesis with an overall success rate greater 
than 80% for the fi rst treatment attempt [ 25 , 26• ]. In addi-
tion, an external validation has been published recently 
[ 27 ]. Antimicrobial treatment of implant-associated infec-
tion without any surgical intervention usually results in 
failure. The following surgical options should be chosen 
according to well-defi ned criteria [ 2 ].
 Débridement with retention
 The success rate of this procedure is widely underestimated, 
because patients were often included without proper selection 
and it has often been used for suppression, not cure [ 28–31 ]. 
The success rate is as high as for exchange surgery (> 80%) if 
the following conditions are fulfi lled: 1) a stable implant, 2) 
a pathogen with susceptibility to antimicrobial agents active 
against surface-adhering microorganisms, 3) absence of a 
sinus tract or a periprosthetic abscess, and 4) duration of 
infection symptoms less than 3 weeks [ 22 , 24 , 25 , 26• ]. 
 One-stage exchange
 One-stage exchange includes removal and reimplantation 
during the same surgical procedure. Patients with intact or 
 Figure 1.  Surgical treatment algorithm for 
prosthetic joint–associated infections.  Asterisk 
indicates difﬁ cult-to-treat microorganisms: 
methicillin-resistant  Staphylococcus aureus , 
enterococci, small-colony variants of staphy-
lococci, quinolone-resistant  Pseudomonas 
aeruginosa , any type of multidrug-resistant 
microorganism, and fungi.
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only slightly compromised soft tissue qualify for this pro-
cedure, reaching a success rate of 86% to 100% [ 32 , 33 ]. A 
two-stage revision with a long interval is preferred if resis-
tant or diffi cult-to-treat microorganisms are causing the 
infection, such as methicillin-resistant  S. aureus (MRSA), 
small-colony variants of staphylococci [ 34• ], enterococci, 
quinolone-resistant  Pseudomonas aeruginosa, or fungi. 
 Two-stage exchange
 Two-stage exchange includes removal of the prosthe-
sis with implantation of a new prosthesis during a later 
surgical procedure. A short interval until reimplantation 
(2–4 weeks) and a temporary antimicrobial-impregnated 
bone cement spacer may be used in most cases. However, 
if diffi cult-to-treat microorganisms are isolated, a longer 
interval (8 weeks) without a spacer is preferred. The two-
stage procedure can be used for every patient and has a 
success rate generally exceeding 90% [ 2 , 35 ]. However, 
the two-stage exchange is diffi cult and time-consuming, 
and the functional result may be suboptimal due to repeti-
tive surgery resulting in bone and muscle destruction [ 2 ]. 
Therefore, it should be chosen when less invasive surgical 
modalities are not appropriate.
 Permanent removal
 Permanent removal of the device is usually reserved for 
patients with a high risk of reinfection (eg, severe immu-
nosuppression, active intravenous drug use) or a functional 
improvement after reimplantation is not expected. Alterna-
tively, long-term antimicrobial suppression may be chosen 
if the patient is inoperable, bedridden, or debilitated. How-
ever, suppressive therapy only controls clinical symptoms 
and infection relapse occurs in most patients (> 80%) when 
antimicrobials are discontinued.
 Bone cement
 Use of antibiotic-loaded bone cement is controversial 
because no double-blinded randomized studies are avail-
able [ 36 ]. In a prospective multicenter study involving 1688 
patients with primary implant fi xation, the infection rate 
was 0.8% vs 1.9% without antibiotic-loaded cement [ 37 ]. 
However, due to lack of controlled trials, the clinical effi cacy 
of antibiotic-loaded cement remains uncertain in primary 
implantation. In contrast, the use of antibiotic-loaded bone 
cement in patients with hip prosthesis–associated infec-
tion treated with one-stage exchange is less controversial. 
In a summary of 29 studies, the cure rate was signifi cantly 
higher in patients treated with antibiotic-impregnated bone 
cement (86% vs 59%) [ 35 ]. 
 Surgical therapy in patients with fracture-fi xation devices
 The two treatment goals in patients with fracture-fi xation 
devices are consolidation of the bone fracture and prevention 
of chronic osteomyelitis. Unlike in patients with prosthetic 
joints, eradication of infection is not always required because 
the device can often be removed after consolidation. There 
are different types of infection, namely pin-track infection, 
osteomyelitis after plating, and osteomyelitis after intramed-
ullary nailing. We recently reviewed the treatment principles 
of these infections [ 38• ]. 
 Antimicrobial therapy
 Table 2 summarizes antimicrobial agents according to 
the pathogen and its antimicrobial susceptibility [ 2 ]. In 
the presence of an implanted device, the type and length 
of antimicrobial therapy are crucial. Due to persistence 
of microorganisms in the biofi lm, infection commonly 
recurs with inappropriate antibiotic choice and/or dura-
tion. The necessary duration of treatment is based on 
case series and one controlled study [ 2 , 22 ]. We suggest 
treatment duration of 3 months (6 months for knee pros-
theses), administered intravenously for the fi rst 2 weeks, 
and followed by oral therapy if a drug with good oral bio-
availability is available. 
 The treatment course can be shortened to 6 weeks if all 
foreign material is removed and no spacer implanted dur-
ing a two-stage surgery. In this situation, persistence of a 
device-associated biofi lm can be avoided. After 6 weeks of 
treatment, device reimplantation should be delayed by an 
additional 2 weeks to obtain reliable tissue specimens for 
culture to document treatment success. After reimplanta-
tion, antimicrobial therapy is initially readministered and 
then discontinued if intraoperative cultures remain nega-
tive; otherwise treatment is continued for 3 months (6 
months for knee prostheses). 
 In cases of rifampin-susceptible staphylococcal implant 
infections, rifampin-combination regimens should be 
used, because of the excellent activity of rifamycins on 
slow-growing and adherent staphylococci [ 22 ]. These 
properties of rifampin have been shown in vitro, in animal 
models, and in several clinical studies [ 19–23 , 25 , 26• , 39• ]. 
Rifampin must be combined with another drug to prevent 
emergence of resistance in staphylococci. Newer rifamycin 
derivatives (eg, ABI-0043) have proved to have effi cacy 
comparable to rifampin in an animal model of foreign-
body infection [ 39• ]. Unfortunately, emerging resistance 
is a problem common to all known rifamycins. Recently, 
a hybrid antibiotic compound, CBR-2092 (Cumbre Phar-
maceuticals, Dallas, TX), a fusion rifamycin-quinolone 
drug, has been developed. This represents a new and 
interesting class of investigational antibiotics that can be 
given as monotherapy [ 40 ]. 
 Fluoroquinolones are the main drugs combined with 
rifampin in staphylococcal infections [ 2 , 22 , 23 ]. Their chief 
advantages are good bioavailability, activity, and safety. Clas-
sic fl uoroquinolones (eg, ciprofl oxacin or pefl oxacin) have 
been replaced by newer ones (moxifl oxacin, levofl oxacin, 
and gatifl oxacin), which have an improved in vitro activity 
against quinolone-susceptible staphylococci and favorable 
pharmacokinetics. In contrast to older quinolones, no con-
trolled clinical trials of implant-associated infection with 
a suffi cient follow-up period have been performed. Newer 
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 Table 2. Treatment of implant-associated infections  
 Microorganism  Antimicrobial agent*  Dose  Route 
 Staphylococcus spp. 
 Methicillin-susceptible  Rifampin plus   450 mg every 12 h  PO/IV 
 Nafcillin or (ﬂ u)cloxacillin †  
for 2 wk, followed by 
 2 g every 6 h  IV 
 Rifampin plus  450 mg every 12 h  PO 
 Levoﬂ oxacin or  750 mg every 24 h to 500 mg 
every 12 h 
 PO 
 Ciproﬂ oxacin   750 mg every 12 h  PO 
 Methicillin-resistant  Rifampin plus  450 mg every 12 h  PO/IV 
 Vancomycin or  1 g every 12 h ‡  IV 
 Daptomycin 
for 2 wk, followed by 
 6 mg/kg every 24 h  IV 
 Rifampin plus  450 mg every 12 h  PO 
 Levoﬂ oxacin or  750 mg every 24 h to 500 mg 
every 12 h 
 PO 
 Ciproﬂ oxacin or  750 mg every 12 h  PO 
 Teicoplanin §  or  400 mg every 24 h  IV/IM 
 Fusidic acid or  500 mg every 8 h  PO 
 Cotrimoxazole or  1 DS tablet every 8 h ¶  PO 
 Minocycline or  100 mg every 12 h  PO 
 Clindamycin  300 mg every 6 h  PO 
 Streptococcus spp.  Penicillin G †  or  5 million U every 6 h  IV 
 ceftriaxone  2 g every 24 h for 4 wk, 
followed by 
 IV 
 Amoxicillin  750–1000 mg every 8 h  PO 
 Enterococcus spp. 
(penicillin-susceptible) 
 Penicillin G or  5 million U every 6 h  IV 
 Ampicillin or amoxicillin plus 
aminoglycoside** 
for 2–4 wk, followed by 
 2 g every 4–6 h  IV 
 Amoxicillin  750–1000 mg every 8 h  PO 
 Enterobacteriaceae 
(quinolone-susceptible) 
 Ciproﬂ oxacin  750 mg every 12 h  PO 
 Nonfermenters 
(eg, Pseudomonas 
aeruginosa) 
 Cefepime or ceftazidime plus 
aminoglycoside** 
for 2 to 4 wk, followed by 
 2 g every 8 h  IV 
 Ciproﬂ oxacin  750 mg every 12 h  PO 
 Anaerobes ††  Clindamycin 
for 2–4 wk, followed by 
 600 mg every 6–8 h  IV 
 Clindamycin  300 mg every 6 h  PO 
 *For total duration of antimicrobial treatment, see text.
 † In patients with delayed hypersensitivity, cefazolin (2 g every 8 h IV) can be administered. In patients with immediate hypersensitivity, 
penicillin should be replaced by vancomycin (1 g every 12 h IV).
 ‡ Alternatively, vancomycin may be administered as continuous infusion (30 mg/kg/d).
 § First 1–3 days of treatment, teicoplanin dose should be increased to 800 mg IV.
 ¶ DS (Forte) tablet—trimethoprim 160 mg plus sulfamethoxazole 800 mg.
**Aminoglycosides can be administered in a single daily dose.
 †† Alternatively, penicillin G (5 million U every 6 h IV) or ceftriaxone (2 g every 24 h IV) can be used for gram-positive anaerobes 
(eg, Propionibacterium acnes), and metronidazole (500 mg every 8 h IV or PO) for gram-negative anaerobes (eg, Bacteroides spp.).
IM—intramuscular; IV—intravenous; PO—oral. 
 (Adapted from Zimmerli et al. [ 2 ].)    
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quinolones were studied in experimental bone infections 
[ 41 ], but only anecdotal clinical data exist for levofl oxacin 
and moxifl oxacin, respectively [ 26• ]. One of the problems 
of long-term therapy with fl uoroquinolones is the risk of ten-
donitis, which can occur with all fl uoroquinolones, and is 
therefore a class effect.
 Other oral combination partners for rifampin include 
cotrimoxazole, clindamycin, minocycline, and linezolid; 
however, clinical data in prosthetic joint infections are 
scarce. Nevertheless, such combinations have similar 
effi cacy as quinolone combinations, because the crucial 
drug is rifampin and the partner drug is primarily serving 
to prevent the emergence of resistance. In contrast, more 
information is available on linezolid treatment [ 42 , 43 ]. In 
the study by Soriano et al. [ 42 ], 85 patients with acute 
or chronic orthopedic device–associated infections due 
to methicillin-resistant staphylococci were treated either 
with linezolid alone or with a linezolid/rifampin combina-
tion. The cure rate was high in both groups if the implant 
was removed (92% and 100%, respectively). In patients 
with retained implant and less than 2 weeks of infection 
symptoms, linezolid alone was less effi cacious than in 
combination with rifampin (60% vs 88%). However, in 
patients with chronic infection, the cure rate was low in 
both groups (40% vs 47%). This confi rms that débride-
ment with retention should be reserved for patients with 
short duration of infection [ 2 , 44 ]. Toxicity is a major 
concern with prolonged linezolid treatment (> 21 days). 
Reversible myelosuppression is frequent (10%) and irre-
versible neuropathy occasionally occurs [ 43 ]. 
 Daptomycin is a lipopeptide antibiotic active against 
several gram-positive bacteria, including MRSA, van-
comycin-resistant  S. aureus , and vancomycin-resistant 
enterococci (VRE) [ 45 ]. Its effi cacy has been tested in an 
animal model of implant-associated infections, where it 
showed no advantage compared with vancomycin or tei-
coplanin [ 19 ]. In a recently published series of 12 patients 
with prosthetic joint–associated infection, a 6-week 
course with daptomycin (4 mg/kg per day) failed in half 
of the cases [ 46 ]. In patients with more than 2 weeks of 
symptoms of infection, foreign material was removed and 
the failure rate was 2 of 7 (26%). In contrast, the treat-
ment failed in 4 of 5 patients (80%) with débridement 
and implant retention. None of these patients received a 
combination with rifampin, which could explain the high 
failure rate of infections with implant retention.
 Hematogenous Infection
 Patients with orthopedic implants are at lifelong risk for 
hematogenous infection. Exogenous infections acquired 
either intra- or perioperatively are usually manifested 
during the fi rst 2 years after implantation. During this 
same period, the risk of hematogenous infection is also 
higher and differentiating between exogenous and hema-
togenous infection is diffi cult, especially if the patient 
has no detectable distant focus. In two of our studies, 
we analyzed the pathogenesis of infection. We found 
that 43% (27/63) of the total hip arthroplasty–associ-
ated infections were hematogenously acquired. Three 
quarters of them were late infections [ 25 ]. In the second 
study, a series of total knee arthroplasty–associated 
infection, 37.5% were of hematogenous origin, and 
most of these were late infections [ 26• ]. Similarly, in 
the study by Maderazo et al. [ 47 ] 35% of the prosthetic 
joint–associated infections occurred after the fi rst year. 
Thus, patients with orthopedic implants remain prone to 
implant-associated infection throughout their lives. 
 Studies on the pathogenesis of implant-associated infec-
tion show a locally acquired granulocyte defect [ 48 , 49 ]. 
Accordingly, the minimal infecting dose for an implant-
associated abscess is as low as 100 colony-forming units 
 Table 2. Treatment of implant-associated infections  
 Microorganism  Antimicrobial agent*  Dose  Route 
 Mixed infections 
(without methicillin-resistant 
staphylococci) 
 Amoxicillin/clavulanic acid  2.2 g every 8 h  IV 
 or piperacillin/tazobactam  4.5 g every 8 h  IV 
 or imipenem  500 mg every 6 h  IV 
 or meropenem  1 g every 8 h  IV 
 For 2–4 wk, followed by 
individual regimens according 
to antimicrobial susceptibility  
 *For total duration of antimicrobial treatment, see text.
 † In patients with delayed hypersensitivity, cefazolin (2 g every 8 h IV) can be administered. In patients with immediate hypersensitivity, 
penicillin should be replaced by vancomycin (1 g every 12 h IV).
 ‡ Alternatively, vancomycin may be administered as continuous infusion (30 mg/kg/d).
 § First 1–3 days of treatment, teicoplanin dose should be increased to 800 mg IV.
 ¶ DS (Forte) tablet—trimethoprim 160 mg plus sulfamethoxazole 800 mg.
**Aminoglycosides can be administered in a single daily dose.
 †† Alternatively, penicillin G (5 million U every 6 h IV) or ceftriaxone (2 g every 24 h IV) can be used for gram-positive anaerobes 
(eg, Propionibacterium acnes), and metronidazole (500 mg every 8 h IV or PO) for gram-negative anaerobes (eg, Bacteroides spp.).
IM—intramuscular; IV—intravenous; PO—oral. 
 (Adapted from Zimmerli et al. [ 2 ].)    
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(CFU) of  S. aureus in an animal model and in human 
volunteers [ 48 , 50 ]. Thus, each implant is a “locus minoris 
resistentiae.” Quantifying the risk for hematogenous infec-
tion is clinically important. At fi rst glance, one would think 
that implants are endangered during episodes of bacteremia 
induced by manipulations such as dental work, especially 
teeth extraction. However, such episodes of bacteremia are 
of short duration and of low bacterial density. The number 
of CFU after dental extraction in children ranges between 
1 and 28 CFU/mL blood and usually does not exceed 15 
minutes [ 51 , 52 ]. We therefore tested the critical bacterial 
density in the bloodstream resulting in permanent infection 
associated with extravascular foreign bodies [ 53 ]. Intracar-
diac inoculation of 5 × 10 7  CFU  S. aureus resulting in 103 
CFU/mL blood was required to selectively induce subcu-
taneous implant–associated infection [ 53 ]. Similarly, in a 
rabbit knee joint model, Blomgren et al. [ 54 ] found that sev-
eral intravascular injections of high doses of  S. aureus were 
required to get prosthetic knee infection. Thus, patients 
with orthopedic implants are endangered during episodes 
of prolonged high-density bacteremia, but clearly not by 
low-density bacteremia observed after different types of 
manipulations (eg, teeth extraction). After teeth extraction, 
one third of the microorganisms are viridans streptococci 
[ 52 ]. In a study of 189 episodes of late infection after total 
joint replacement, only 2.1% were due to viridans strepto-
cocci [ 55 ]. This clinically confi rms that dental work does 
not seriously endanger orthopedic implants. 
 Taken together, hematogenous infections do not occur 
during occasional transient bacteremia, but rather dur-
ing clinically relevant infections. Maderazo et al. [ 47 ] 
reported the highest risk during skin infection. Among 
67 patients with late prosthetic joint–associated infection, 
46% had primary skin infections as the origin, and 66% 
of them were caused by  S. aureus . Among three patients 
in whom infection was considered of dental origin, one 
patient had a dental abscess and one had periodontitis. 
Only one occurred after dental extraction. In all three 
cases, the microorganism was not typical for dental origin 
( S. aureus ,  Staphylococcus epidermidis , and  P. acnes ). 
With regard to hematogenous seeding,  S. aureus is asso-
ciated with the highest risk for hematogenous prosthetic 
joint-associated infection. Murdoch et al. [ 56 ] reported 
a risk of 34% of hematogenous infection in 44 patients 
with a prosthetic joint and  S. aureus bacteremia. 
 The 2003 Advisory Statement from the American 
Dental Association and the American Academy of Ortho-
paedic Surgeons on antibiotic prophylaxis for dental 
patients with prosthetic joints concludes that scientifi c 
evidence does not support that antibiotic prophylaxis 
is required to prevent hematogenous infection during 
dental treatment [ 57 ]. Nevertheless, prophylaxis should 
be considered in certain high-risk patients. However, 
this latter statement is not based on scientifi c data. We 
suggest performing necessary dental work before joint 
replacement and avoiding it during the fi rst year after 
implantation, if possible. More important than antibi-
otic prophylaxis is the rapid and adequate treatment of 
any infection. Because skin infections such as cellulitis or 
erysipelas pose the greatest risk, the patient must be edu-
cated to consult an experienced physician immediately. 
In addition, during or after such infections, especially 
after  S. aureus bacteremia, prosthetic joint–associated 
infection must be considered. 
 Conclusions
 In the future, the apparent incidence of prosthetic joint–
associated infection will increase further due to 1) better 
detection methods for microbial biofi lms involved in pros-
thetic joint infections, 2) the growing number of implanted 
prostheses in the aging population, and 3) the increasing 
residency time of prostheses, which are at lifelong risk for 
hematogenous infection.
 Better understanding of the interaction among microor-
ganisms, implant, and host may further improve our current 
approach to the diagnosis and treatment of implant-asso-
ciated infections. The controversy regarding suppressive 
versus curative therapy should be clarifi ed. If the properly 
selected patient is treated with the correct procedure, in 
most cases cure can be reached, and no long-term suppres-
sive antibiotic therapy is needed. The rational choice of the 
optimal treatment modality should be based on duration of 
the infection, stability of the implant, antimicrobial suscep-
tibility of the pathogen, and condition of the surrounding 
soft tissue. If all criteria are correctly considered, cure rates 
between 70% and 90% are the rule. 
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